Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Nat Nanotechnol. 2014 May 11;9(8):648–655. doi: 10.1038/nnano.2014.84

Table 3.

Target gene expression in (B) cardiovascular, (C) renal, and (D) hepatic vasculature following injection of 7C1 complexed with siRNA targeting Luc or Tie1, Tie2, VE-cad, VEGFR-2, and ICAM2. (A) Importantly, a 1 mg/kg total dose consisted of 0.075 mg/kg siVE-cad, 0.125 mg/kg siICAM2, 0.25 mg/kg siVEGFR-2, 0.25 mg/kg siTie2, and 0.30 mg/kg siTie1.

a
graphic file with name nihms-577487-f0005.jpg
b
Total Dose (mg/kg) 2.0 siLuc l.5 si 5 genes 1.0 si 5 genes 0.5 si 5 genes 0.25 si 5 genes
Tiel 1.02 ± 0.16 0.15 ± 0.02 0.22 ± 0.05 0.33 ± 0.08 0.60 ± 0.06
Tie2 0.90 ± 0.08 0.37 ± 0.02 0.43 ± 0.02 0.38 ± 0.04 0.56 ± 0.03
VE-cad 0.88 ± 0.18 0.26 ± 0.01 0.31 ± 0.07 0.49 ± 0.13 0.75 ± 0.09
VEGFR-2 0.99 ± 0.13 0.22 ± 0.03 0.23 ± 0.03 0.41 ± 0.09 0.65 ± 0.04
ICAM2 1.15 ± 0.26 0.24 ± 0.04 0.34 ± 0.09 0.65 ± 0.28 1.13 ± 0.14
c
Tie1 1.22 ± 0.15 0.25 ± 0.03 0.31 ± 0.04 0.48 ± 0.08 0.87 ± 0.11
Tie2 1.35 ± 0.19 0.31 ± 0.04 0.32 ± 0.03 0.48 ± 0.09 0.92 ± 0.09
VE-cad 0.92 ± 0.06 0.49 ± 0.16 0.67 ± 0.03 0.73 ± 0.14 1.19 ± 0.07
VEGFR-2 1.46 ± 0.27 0.32 ± 0.08 0.54 ± 0.09 0.93 ± 0.14 0.93 ± 0.13
ICAM2 1.24 ± 0.24 0.54 ± 0.11 0.65 ± 0.08 0.89 ± 0.14 1.23 ± 0.07
d
Tie1 1.15 ± 0.20 0.65 ± 0.12 0.78 ± 0.12 0.89 ± 0.15 0.84 ± 0.15
Tie2 0.92 ± 0.15 0.56 ± 0.12 0.80 ± 0.10 0.79 ± 0.04 0.67 ± 0.23
VE-cad 1.17 ± 0.48 0.77 ± 0.11 0.98 ± 0.22 0.96 ± 0.14 0.85 ± 0.22
VEGFR-2 0.90 ± 0.20 0.81 ± 0.10 0.95 ± 0.20 0.88 ± 0.10 0.86 ± 0.15
ICAM2 1.15 ± 0.33 1.08 ± 0.13 1.42 ± 0.22 1.07 ± 0.09 0.93 ± 0.10